Genmab A/S (Genmab A/S) Net Change in Cash : $712 Mil (TTM As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Genmab A/S Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Genmab A/S's Net Change in Cash for the three months ended in Dec. 2023 was $87 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was $712 Mil.

Genmab A/S Net Change in Cash Historical Data

The historical data trend for Genmab A/S's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab A/S Net Change in Cash Chart

Genmab A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Change in Cash

Get a 7-Day Free Trial

449.06

606.34

257.86

133.28

727.75

Genmab A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Change in Cash	Get a 7-Day Free Trial															-68.92	344.50	-205.76	486.43	86.91

Genmab A/S Net Change in Cash Calculation

Genmab A/S's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	1079.768	+	-187.569	+	-88.664	+	-75.789
	=	728

Genmab A/S's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 244.63 + -64.669 + -3.219 + -89.834

= 87

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $712 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab A/S Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Genmab A/S's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab A/S (Genmab A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (OTCPK:GNMSF) » Definitions » Net Change in Cash

Comparable Companies

OCSE:ZEAL OCSE:ALK B OCSE:BAVA OCSE:GUBRA OCSE:PEG OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX ALNY BGNE BMRN SZSE:300122 RPRX

Traded in Other Exchanges

GMAB:USA GMAB:Mexico GMABc:UK 0MGB:UK GMAB:Denmark GE91:Germany

Address

Kalvebod Brygge 43, Copenhagen, DNK, 1560

Website

https://www.genmab.com

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab A/S (Genmab A/S) Headlines

From GuruFocus

New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody� CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
By Business Wire • 12-09-2023

Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY�/TEPKINLY�) for the Treatment of Relapsed/Refractory Follicular Lymphoma
By Business Wire • 11-27-2023

Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK�) in Patients with Head and Neck Squamous Cell Carcinoma
By Business Wire Business Wire • 02-24-2022

Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023
By Business Wire Business Wire • 06-09-2023

Genmab Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (BLA) for Epcoritamab (DuoBody�-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
By Business Wire Business Wire • 11-21-2022

Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress
By Business Wire Business Wire • 05-25-2023

Top 5 2nd Quarter Trades of Lester Murray Antman dba SimplyRich
By GuruFocus Research GuruFocus Editor • 07-22-2022

TIVDAK� (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
By Business Wire • 01-09-2024

Thinking about trading options or stock in Monday.Com, Boeing, Eli Lilly, Xpeng, or Genmab?
By PRNewswire • 11-14-2023

Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY�) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
By Business Wire • 07-21-2023